Meibomian Gland Dysfunction Management

Sponsor
University of the Incarnate Word (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03652337
Collaborator
American Academy of Optometry (Other)
60
1
2
11
5.5

Study Details

Study Description

Brief Summary

The purpose of this study is to compare electronic debridement of the eyelid margin (BlephEx) to manual debridement of the eyelid margin as treatment options for patients intolerant to contact lens wear consequent to Meibomian gland dysfunction.

Condition or Disease Intervention/Treatment Phase
  • Device: BlephEx
  • Device: Manual debridement
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Meibomian Gland Dysfunction Management to Relieve Contact Lens Discomfort
Actual Study Start Date :
May 10, 2018
Anticipated Primary Completion Date :
Dec 1, 2018
Anticipated Study Completion Date :
Apr 10, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: BlephEx

The subjects who are enrolled in this arm will undergo electronic lid margin debridement using the BlephEx instrument.

Device: BlephEx
Electronic lid margin debridement

Experimental: Manual debridement

The subjects who are enrolled in this arm will undergo manual lid margin debridement using a stainless steel ophthalmic golf spud.

Device: Manual debridement
Manual lid margin debridement

Outcome Measures

Primary Outcome Measures

  1. Symptomatic relief [60 days]

    Betterment of symptoms (improvement in contact lens discomfort) will be measured using two different surveys - Ocular Surface Disease Index (OSID) and Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8). The OSDI scores can range from 0 to 100. The CLDEQ-8 scores can range from 0 to 37. In both the questionnaires, a lowering of the score during follow-up visits represents a betterment of symptoms suffered by the patient. The numerical change in the scores on these two questionnaires will be documented as the change in symptom profile of the patient (betterment / worsening / stability).

Secondary Outcome Measures

  1. Meibography [60 days]

    Meibomian gland imaging will be performed to document any changes in the Meibomian gland during the study period.

  2. Lissamine green staining grade of the lid margin [60 days]

    The lid margin will be stained with Lissamine green dye. For the purpose of this study, Lissamine green staining of the eyelid margins will be graded from 0 to 4. (Zero representing "normal" or "no" staining; Four representing the highest degree of staining). During the course of the study, a decrease in lid margin staining will indicate a betterment of the health of the eyelid margin.

  3. Inflammatory activity [60 days]

    The presence or absence of Matrix Metalloproteinase-9 (MMP-9) in the tear fluid will be documented during the study visits. Presence of MMP-9 in the tear fluid indicates the presence of inflammatory activity in the tear fluid.

  4. Tear break-up time [60 days]

    Improvement in non-invasive tear break-up time measurement will be an objective outcome of the study.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Habitual contact lens wearers whose contact lens wear time has reduced due to MGD will be preferentially considered for this study. Subjects who currently cannot wear contact lenses due to MGD may be considered on a case-by-case basis.
Exclusion Criteria:
  • Subjects who are currently using any prescription ophthalmic medications (such as antibiotics, steroids and immunomodulatory drugs) will be excluded from participation.

  • Subjects who have active ocular infections will be excluded from participation.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rosenberg School of Optometry San Antonio Texas United States 78229

Sponsors and Collaborators

  • University of the Incarnate Word
  • American Academy of Optometry

Investigators

  • Principal Investigator: Srihari Narayanan, OD, PhD, Professor

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of the Incarnate Word
ClinicalTrials.gov Identifier:
NCT03652337
Other Study ID Numbers:
  • 18-04-003
First Posted:
Aug 29, 2018
Last Update Posted:
Sep 5, 2018
Last Verified:
Sep 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 5, 2018